2-Imidazolidinone → (S)-2-tert-butoxy-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-methyl-1H-indazol-5-yl)-2-oxoimidazolidin-1-yl)benzo[d]thiazol-6-yl)acetic acid
反応式
[C:1]([O:5][C@@H:6]([C:10]1[C:35]([CH3:36])=[CH:34][C:13]2[N:14]=[C:15]([N:17]3C[CH2:21][CH2:20][N:19]([C:23]4[CH:24]=[C:25]5[C:29](=[CH:30][CH:31]=4)[N:28]([CH3:32])[N:27]=[CH:26]5)[C:18]3=[O:33])[S:16][C:12]=2[C:11]=1[C:37]1[CH:42]=[CH:41][C:40]([Cl:43])=[CH:39][CH:38]=1)[C:7]([OH:9])=[O:8])([CH3:4])([CH3:3])[CH3:2].N1CCNC1=O>>[C:1]([O:5][C@@H:6]([C:10]1[C:35]([CH3:36])=[CH:34][C:13]2[N:14]=[C:15]([N:17]3[CH2:21][CH2:20][N:19]([C:23]4[CH:24]=[C:25]5[C:29](=[CH:30][CH:31]=4)[N:28]([CH3:32])[N:27]=[CH:26]5)[C:18]3=[O:33])[S:16][C:12]=2[C:11]=1[C:37]1[CH:38]=[CH:39][C:40]([Cl:43])=[CH:41][CH:42]=1)[C:7]([OH:9])=[O:8])([CH3:2])([CH3:4])[CH3:3]参加物
3
反応物 2
生成物 1
実験手順
(S)-2-tert-butoxy-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-methyl-1H-indazol-5-yl)-2-oxoimidazolidin-1-yl)benzo[d]thiazol-6-yl)acetic acid (1.3 mg) was prepared in a similar manner as compound (S)-2-tert-butoxy-2-(7-(4-chlorophenyl)-5-methyl-2-(3-(1-methyl-1H-indazol-5-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)benzo[d]thiazol-6-yl)acetic acid except using imidazolidin-2-one instead of tetrahydropyrimidin-2(1H)-one. LCMS-ESI+: calc'd for C31H30ClN5O4S: 604.2 (M+H+); Found: 604.2 (M+H+); 1H-NMR 400 MHz, (CD3OD) δ 7.99 (s, 1H), 7.82 (m, 1H), 7.66 (m, 1H), 7.60-7.48 (m, 5H), 7.42 (m, 1H), 5.21 (s, 1H), 4.33 (m, 1H), 4.22 (m, 2H), 4.06 (s, 3H), 3.64 (m, 1H), 2.55 (s, 3H), 0.96 (s, 9H).
出典と根拠
- ORDレコード
- ord-3cc4e9178b8840f4b6bb5d63e5cede54
- 出典データセット
- uspto-grants-2015_08
- 特許番号
- US09096586B2
反応ノート
読み込み中…